Abalos Therapeutics Launches with €12M Series A
Abalos Therapeutics launches with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds. Abalos, which
Orion Biotechnology to Initiate Clinical Trials of Its Innovative Microbicide Gel for HIV Prevention
Orion Biotechnology announced that the Polish National Regulatory Agency and Local Ethics Committee have given approval for the OB-002H-101 Phase 1 safety and acceptability study of OB-002H gel to start screening and enrollment. The OB-002H gel is a topical formulation